Sunday, May 31, 2015

Three Secrets Wall Street Is Terrified You’ll Discover

It was Sir Francis Bacon who gave us the truism that "knowledge is power."

And the 17th century English philosopher and statesman did so centuries before Wall Street was even conceived.

But the brokers, fund managers, and other pros who dreamed up the investment markets knew a good thing when they saw it. They embraced Bacon's maxim, launched the first U.S. stock exchange in 1790, and spent the next two centuries transforming this country's individual investors into scared vassals of the Wall Street elite.

And the big banks, brokerages, and other investment pros did this by never forgetting the simple precept that "knowledge is power."

I see this play out on an almost-daily basis thanks to the endless streams of impenetrable reports that come from the bankers in New York or our elected leaders in Washington.

Most Main Street investors lack the knowledge to "decode" these reports, so they also lack the power to respond in a constructive manner.

Instead most of us just react - panic really. An upbeat economic report prompts investors to shoot stocks higher one day. But on the next, a seemingly conflicting report causes share prices to plummet.

Wall Street isn't fazed by this whipsaw trading, of course: As individual investors, we must travel the road that's owned by the pros. And that means we must pay a "toll" - in the form of a commission or transaction fee - with every move we make.

In fact, there's even an incentive to make us take more trips - heading north (bullish) one day and south (bearish) the next: The more trips we take, the more of those "tolls" that we have to pay - and the larger the pile of profits that Wall Street reaps.

investing secretKnowledge isn't just power: It also represents profits... even wealth.

I'm putting such a fine point on this - and telling you about Francis Bacon - for a very specific reason: Thanks to the 30 years I've spent watching and working with Silicon Valley companies, I long ago "cracked the code" that gives Wall Street so much power over America's Main Street investors.

I've identified the three specific economic reports that matter - and have deciphered what they mean. And I know which ones are just claptrap - mind-numbing clutter - designed to maintain the very one-sided status quo.

And today I'm going to give you a backstage pass... so you'll have direct access to that "knowledge" - and the "power" profits that accompany it.

A Backstage Pass

I'm sure that almost all of you - at one time or another - have heard someone talk about a "velvet rope." If so, have you stopped to think about what the term means?

Think about some of the finer places you've visited - a Broadway play, a hot new restaurant, or that just-opened nightclub: As you wait your turn, the "gatekeeper" - a maître d', hostess, or bouncer - keeps you on that "other" side of a literal "velvet rope."

That wait can be long... and frustrating - especially when the "connected" patrons get in before you.

Wall Street plays the same game. The bankers, fund managers, and other pros want to keep you at bay - while giving their best clients first access to the "best-in-show" investments. But in this case, the velvet rope is knowledge - about the relative health of the U.S. and global economies.

And the Wall Street crowd will hate me for telling you this, but the game is nowhere near as complicated as the pros would have you believe. In fact, in assessing the strength of the U.S. economy as I analyze tech plays, I've really found that these three economic "data points" are the most important to follow:

jobs (hiring), autos, and housing.

At its most basic level, this makes complete sense. The jobs situation is the key to U.S. economic health. As much as two-thirds of America's market-based economy is driven by consumer spending. Business spending is also crucial - particularly when it comes to the "stuff" that the tech sector makes.

Hot Beverage Companies To Own For 2016

Consumers and businesses spend the most when they are confident about the future.

And confidence has a lot to do with predictability - like the wage predictability that comes with job stability... or better, still, when there's outright hiring taking place.

When consumers start feeling a bit more secure about the future, they'll ramp up their spending a bit on bigger-ticket items like new vehicles. And when they're really confident, they'll get into even-bigger-ticket purchases - like new houses.

To give you more knowledge - and more power (enough to make you smarter and richer, in fact) - I've used these insights to create three smart-investor indicators.

If enough Main Street investors learn to spot and use these three investing "secrets," Wall Street will find itself at our mercy. And what a day that will be.

Let's peruse each of the three. And we'll start with the basic building block - jobs.

Investing Secret No. 1: Hiring = Confidence

This number, which measures how tech leaders feel about hiring, comes from the Silicon Valley Leadership Group's regular poll of sector chief executive officers (CEOs). According to the organization's most recent poll, more than half the members of the corner-office crowd say they plan to hire more workers this year.

Just think about how you feel when you know that your employer is thinking about expansion - which necessitates hiring: It's definitely a confidence booster.

So if the Silicon Valley cognoscenti expect to hire, it clearly means they are expecting continued strong demand for the products and services their companies offer.

And right now, tech CEOs are bullish. Of the 222 surveyed, 59% plan to hire this year - up from 46% a year ago. In fact, in the most recent survey that appeared in March, most CEOs were worried about not being able to hire enough workers.

Clearly, we don't want to rely on a single survey, no matter how good, to tell us what's happening with employment.

That's why I also keep abreast of the official jobs numbers coming out of Washington.

The U.S. economy added 288,000 jobs in April. That's the fourth-best monthly gain in the recovery's five-year history.

The timing also was great. It came right after Washington told us the economy grew at a dismal 0.1% for the first quarter.

I grant you, that gross domestic product report paints a less-than-upbeat portrait of how healthy America really was during the first three months of the year. But I'm actually not that concerned: I believe that number will be revised upward because of another important set of stats I track regularly ...

Investing Secret No. 2: When Vehicle Sales Zoom, Growth Follows

I've been following the U.S. automobile industry for decades now. As a young analyst, I spent my formative years in Detroit, where I met with CEOs of all the car companies and many of the parts producers.

I've visited assembly plants here in the United States and overseas. I was in Detroit in the very early days of robotics manufacturing. I also witnessed the rollout of computer technology that improved the performance, reliability, and fuel economy of new cars and trucks.

As heady as those days were, they've been dramatically eclipsed by today's vehicles, each of which is a high-tech "ecosystem" unto itself. They're brimming with sensors, semiconductors, LEDs, GPS, wireless web communications systems, and much more.

In fact, the Institute of Physics says that NASA sent the Apollo astronauts to the moon back in 1969 using less computing power than you'll find in the typical family car. Today's typical luxury car has more than 100 million lines of computer code, while software and electronics account for 40% of the car's cost and half of warranty claims.

So it's no surprise that auto sales are a strong indicator of the health of Silicon Valley.

And I'm very happy to report to you that the U.S. auto industry has snapped back after a tough winter and is racing ahead.

In April, the industry sold 1.39 million new vehicles, an 8% increase from the year-ago period. On an adjusted basis, the surge pushed the annualized run rate to 16.1 million, a yearly gain of 6%.

I also like to get the pulse of the industry by looking at what the automakers are projecting for total industry sales.

And every single major automaker polled so far expects total cars and trucks sold this year to hit at least 16 million units, compared with 2013's final tally of 15.3 million.

Clearly, job growth and auto sales are crucial barometers of the health of the American economy.

But there's one other metric that is critical for us to understand if we're to start making smarter investments...

Investing Secret No. 3: Housing Heals the Bulls

There's a good reason why Uncle Sam lets you deduct mortgage interest payments from your taxes: A healthy housing industry is a major catalyst for economic growth.

And it's not just the millions of construction and home-contractor jobs that are involved. A healthy housing market also means more sales of appliances, furniture, home furnishings, paint, and lumber - as well as the equipment for home-entertainment systems and in-house Wi-Fi networks.

Right now, a lot of analysts see trouble brewing. Sales of new homes fell 13% in March from a year ago. Plus, sales of existing homes have fallen for several months.

But I'm not worried about these numbers - and for two very strong reasons.

First, severe winter weather in much of the country shut down construction. And it kept many prospective homebuyers indoors. It also prevented many home-improvement projects from being completed, a fact the mainstream media seems to be ignoring.

Second, sales of existing homes have declined because the supply of distressed housing continues to fall. In other words, we don't have an oversupply of homes; there aren't enough homes to satisfy demand.

Put more simply: You can't sell what you don't have.

I came to this conclusion courtesy of another housing stat. Data provider CoreLogic Inc. (NYSE: CLGX) says average housing prices rose 11% in March compared with the same month in 2013.

CoreLogic didn't provide median price estimates. But the company did say that we've seen higher annualized housing prices for 25 straight months.

Putting It All Together

As most of you folks know, one of my investing mantras tells us to "separate the signal from the noise." As I see it, these three signals are telling us that America's economy is healthy and growing. Tech CEOs are still hiring, new cars and trucks are moving off lots at near-record levels, and the demand for homes still exceeds supply.

I know some investors keep an eye on a longer list of economic indicators. And in their own attempts at subterfuge, the Wall Street pros try to bury us with an avalanche of often contradictory indicators... the goal being to keep the knowledge and the power on their side of the investment velvet rope.

But the goal here is to cut through the clutter and get a quick snapshot of what's reallyhappening with the economy.

By focusing on the three investing "secrets" listed above - those key signals of hiring, auto sales, and housing-market health - you'll cut through most of the noise. You'll have the knowledge... and the power.

And that will make you a smarter, more profitable investor - and will put you on the path to meaningful wealth.

Stop back later this week.

Editor's Note: For the last 12 months, Michael has been hot on the trail of something called Operation BlueStar. It surrounds a mysterious facility - about the size of 174 football fields - being built here in the United States... a facility that could single-handedly disrupt $737 billion of America's economy. Michael's investigation has led him to one of the most exciting investment opportunities we've ever come across. Click here so Michael can walk you through everything he dug up.

Saturday, May 30, 2015

Top Transportation Stocks To Invest In 2016

Top Transportation Stocks To Invest In 2016: YRC Worldwide Inc.(YRCW)

YRC Worldwide Inc., through its subsidiaries, provides various transportation services worldwide. The company?s YRC National Transportation unit offers a range of services for the transportation of industrial, commercial, and retail goods, such as apparel, appliances, automotive parts, chemicals, food, furniture, glass, machinery, metal, metal products, non-bulk petroleum products, rubber, textiles, wood, and other manufactured products. It serves manufacturing, wholesale, retail, and government customers. As of December 31, 2009, it had 11704 owned tractors, 1239 leased tractors, 50083 owned trailers, and 3244 leased trailers. Its YRC Regional Transportation unit?s service portfolio includes regional delivery, which comprises next-day local area delivery and second-day services, consolidation/distribution services, protect-from-freezing and hazardous materials handling, and various specialized offerings; expedited delivery, that comprises day-definite, hour-definite, and time definite capabilities; inter-regional delivery; cross-border delivery; and operation of my.yrcregional.com and NewPenn.com, which are e-commerce Websites offering online resources to manage transportation activity. The company?s YRC Logistics units? service portfolio consists of distribution services that include flow through and pool distribution, dedicated warehousing, and value-added services; global services, which comprise international freight forwarding, customs brokerage, and value-added services; and transportation services, such as truckload brokerage, domestic freight forwarding, and transportation management. Its YRC Truckload unit provides customized truckload services on regional and national level through the use of company and team-based drivers. The company was founded in 1924 and is headquartered in Overland Park, Kansas.

Advisor! s' Opinion:
  • [By Michael Calia]

    Trucking company YRC Worldwide Inc.(YRCW) said Friday it had cut its large debt load by about $300 million while offering $250 million in stock, the proceeds of which will be used to retire convertible notes. About $50 million in the principal amount of other convertible notes were swapped or converted to common stock, the company said.

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Delta Air Lines Inc.(DAL), NuPathe Inc.(PATH) and YRC Worldwide Inc.(YRCW)

  • [By DailyFinance Staff]

    Job creation last month was shockingly weak, but analysts couldn't really explain why –- other than to blame the weather -- which left investors unsure how to react Friday. Many analysts say the numbers are likely to be revised higher next month, and in the end, market reaction was muted. The Dow Jones industrial average (^DJI) lost ground for a third straight day, declining nearly 8 points, but the Standard & Poor's 500 index (^GPSC) added 4, and the Nasdaq composite index (^IXIC) rose 18 points. Target (TGT) lost more than a point after saying the data breach that began on Black Friday was much worse than previously thought. The company now says as many as 70 million customers had personal information stolen. Target also lowered its fourth quarter outlook, partly because sales slumped after the data breach was first revealed. Sears (SHLD) tumbled by around 13.5 percent. It expects a big quarterly loss as sales fell during the holiday shopping season. Several smaller, specialty retailers also fell: Pacific Sunwear (PSUN) slid 16 percent, Five Below (FIVE) fell 7 percent, Shoe Carnival (SCVL) lost 5 percent, and Conn's (CONN) lost 2 percent. But Abercrombie & Fitch (ANF) jumped 12 percent. It raised its earnings forecast as sales were not as bad as expected. Elsewhere, Alcoa (AA) fell about 5.5 percent. It's not quite the economic bellwether! it used ! to be, but the aluminum giant still matters, and its net came in a bit shy of expectations. YRC Worldwide (YRCW) tumbled 13 percent after workers rejected a contract offer. That has raised fears the trucking company could be forced into bankruptcy. On the upside, the weak jobs report could keep mortgage rates from rising, and that boosted housing stocks. KB Homes (KBH) rose 3 percent, William Lyons up 4 percent, and Lennar (LEN) was up 2 percent. And on Thursday we reported that shares of Intercept Pharmaceuticals nearly quadrupled in price on news of a positive clinical study for its liver dr

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Friday’s session are Alcoa Inc.(AA), Sears Holdings Corp.(SHLD) and YRC Worldwide Inc.(YRCW)

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-transportation-stocks-to-invest-in-2016-2.html

Thursday, May 28, 2015

5 Best Sliver Stocks To Own Right Now

What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.

Company

May 10

Weekly Gain

Inteliquent (NASDAQ: IQNT  )

$5.68

19%

Cliffs Natural Resources (NYSE: CLF  )

$23.53

18%

MAKO Surgical (NASDAQ: MAKO  )

$4.43

13%

MannKind (NASDAQ: MNKD  )

$4.43

13%

Nokia (NYSE: NOK  )

Top Diversified Bank Stocks To Watch Right Now: Midnight Sun Mining Corp (MMA)

Midnight Sun Mining Corp., formerly Midnight Sun Capital Corp., is an exploration-stage company engaged in the acquisition and exploration of mineral property interests in Canada. On May 12, 2010, the Company completed its Qualifying Transaction and entered into a mineral property option agreement with ATAC Resources Ltd. Under the agreement it agreed to acquire a 100% interest in the Arn mineral properties located in the Whitehorse Mining District, Yukon Territory. The Company announced that it has entered into an agreement dated July 28, 2011, with Logwood Investments Inc., a Namibian company (the Optionor), whereby the Company had acquired the option to earn a 60% interest in certain mineral properties in Namibia. The Klein Aub Copper-Silver Property in Namibia includes the seven optioned properties comprising 3,750 square kilometers of Exclusive Prospecting Licences in Namibia. The northern group of three properties are located 90 kilometers south of the capital city of Windhoek. Advisors' Opinion:
  • [By Dividends4Life]

    Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section (see page 2 of the linked PDF for a detailed description):

5 Best Sliver Stocks To Own Right Now: Watson Pharmaceuticals Inc.(WPI)

Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. The company offers its products for therapeutic categories, such as central nervous system, cardiovascular, hormones and synthetic substitutes, anti-infective agents, and urology. It operates in three segments: Global Generics, Global Brands, and Distribution. The Global Generics segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties? brand products. This segment offers various dosage forms, such as oral solids, transdermals, injectables, inhalation products, and transmucosals for indications, including pregnancy prevention, pain management, depression, hypertension, and smoking cessation. The Global Brands segment pr omotes and co-promotes Rapaflo, Gelnique, Trelstar, Androderm, Crinone, ella, INFeD, Generess, sodium ferric gluconate, AndroGel, and Femring branded products; and markets its products through sales professionals. It also sells various non-promoted products. The Distribution segment distributes generic and select brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians? offices. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. Watson Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Parsippany, New Jersey.

Advisors' Opinion:
  • [By Holly LaFon] n Pharmaceuticals stock has been on a decidedly upward trajectory in the last five years, increasing 108 percent. It became slightly cheaper in 2011, however. Dalio has been trading the stock for years but most recently he bought 314,360 shares at about $65 per share in the fourth quarter of 2011 after the stock had ventured off of its 52-week high of $73.35 it climbed to in the middle of the year.

    Watson has a long-term record of profitability and growth, with an 11.9% 10-year revenue per share growth rate and 14.2% 10-year free cash flow per share growth rate.

    Though the stock price declined in late 2011, the company in November reported double-digit net revenue and earnings growth. The company also announced that month an exclusive agreement with Pfizer Inc. (PFE) to launch a generic version of Lipitor, the world�� best-selling drug in the history of pharmaceuticals. It also received approval from the FDA to start producing a generic version of the birth control drug Yaz that month, a drug with sales of $173 million in the 12 months ending Sept. 30, 2011.

    In February, Watson announced a full-year 2011 net revenue increase of 29 percent and EPS increase of 39 percent, due in large part to the successful launch of a total of 189 generic products globally for the year. Currently it is using its strong cash position to invest in growth markets, Canada and European operations.

    In spite of the good news and increasing its full-year revenue forecast by $100 million to about $5.4 billion, the stock is up just 0.05 percent year to date.

    Dalio�� next largest purchase was Berkshire Hathaway Inc. (BRK.B), and three new buys: BCE Inc. (BCE), The Goldman Sachs Group Inc. (GS), and Peabody Energy Corp. (BTU).

    Dalio staking over 32 percent of his fund in emerging markets is tantamount to a forecast that emerging markets will outperform from the macro guru. His other top purchases have clear growth prospects. To see more of what Dalio

  • [By Louis Navellier]

    Actavis Plc is one of the world’s largest generic drugmakers. For the past three decades, this company was known as Watson Pharmaceuticals (WPI), but the company rebranded itself as Actavis in 2013. With a portfolio of over 190 pharmaceutical product families, Actavis has its name on everything from antibiotics to contraceptives to smoking cessation treatments.

5 Best Sliver Stocks To Own Right Now: Ignite Restaurant Group Inc (IRG)

Ignite Restaurant Group, Inc., incorporated on February 4, 2002, operates two restaurant brands, Joe's Crab Shack (Joe's) and Brick House Tavern + Tap (Brick House). The Company�� Joe's Crab Shack and Brick House Tavern + Tap operate in a diverse set of markets across the United States. Joe's Crab Shack is a national chain of casual seafood restaurants serving a variety of seafood items, with an emphasis on crab. Brick House Tavern + Tap is a casual restaurant brand that provides guests a gastro pub experience by offering a blend of menu items. As of December 31, 2012, the Company owned and operated 144 restaurants in 33 states. In September 2013, Ignite Restaurant Group Inc announced the opening of its newest Joe's Crab Shack restaurant, located in Newark, New Jersey.

Joe's Crab Shack

The Company�� Joe's Crab Shack offers an outdoor patio for guests to enjoy eating and drinking and a children's playground. Joe's also has many locations that are located on waterfront property. Interior design elements include a nautical, vacation theme to invoke memories of beach vacations and a genuine crab shack experience. Joe's Crab Shack restaurants have over 200 seats. Many of the Company�� restaurants also include a small gift shop where guests can purchase souvenirs to commemorate their dining experience. Joe's Crab Shack also leverages its crab-forward menu with other crab items, including Made-From-Scratch Crab Cakes, Crab Nachos and Crazy-Good Crab Dip. In addition to its core crab-focused menu, Joe's also offers a range of entrees featuring a variety of seafood, including the Get Stuffed Snapper, Surf 'N Turf Burger and The Big Hook Up, as well as a range of traditional seafood entrees like the Fisherman's Platter. Joe's also offers several out of water options, such as Pan Fried Cheesy Chicken and Whiskey Smoked Ribs. In addition, alcoholic beverages include the Shark Bite, Category 5 Hurricane and Mason Jar cocktails emerging as guests' top choices. Joe's menu inc! ludes more than 29 items made with either Queen, Snow, Dungeness or King Crabs sourced from government regulated and sustainable fisheries. Its menu offers 14 appetizers, including Made-From-Scratch Crab Cakes, Crab Nachos and Crazy-Good Crab Dip, and over 50 entrees, including Steampots, Crab in a Bucket, Skillet Paella, Stuffed Snapper and out of water options like Whiskey Smoked Ribs.

Brick House Tavern + Tap

The Company�� Brick House's interior decor includes custom lighting, dark mahogany woods, open sight lines, high definition television (HD TVs), and an inviting fireplace. In addition to a traditional dining room and bar area, Brick House also offers large communal tables and a section of leather recliners positioned in front of large HD TVs, where guests receive their own TV tray for dining. Outdoor seating is also available on the patio or around an open fire pit at nearly all locations. Both food and beverages are served by personable and engaging service staff. The typical Brick House restaurant is approximately 8,500 square feet and averages approximately 250 seats, which includes both traditional tables and seating options. Brick House offers its guests a selection of contemporary tavern food. Brick House's menu includes 17 appetizers and over 53 entrees. Handcrafted appetizers include Deviled Eggs, Meatloaf Sliders, Brick Pizza, Meat and Cheese Board and Fried Stuffed Olives. Brick House offers an array of burgers, including The Kobe, which is hand formed from American Wagyu beef. Guests can also choose from a selection of homemade entrees, such as Drunken Chops, BBQ Baby Backs, Chicken & Waffles, and its Prime Rib Sandwich. In addition, Brick House's Brick Burgers, include the Gun Show Burger and the Black & Bleu Burger. Brick House's beverage selection includes imported and domestic beers along with hand-pulled cask beer. All Brick House restaurants have a bar that supports a variety of liquor drinks, wine and beer cocktails like the Shandy and Bee Sting, a! s well as! specialty cocktails like the Dark & Stormy, Moscow Mule and The Zombie.

The Company competes with Red Lobster, Bonefish Grill, Landry's Seafood, Bubba Gump Shrimp Company, BJ's Restaurants, Yard House, Cheesecake Factory, Bravo Brio and Buffalo Wild Wings, Applebee's, Chili's, T.G.I. Friday's, Texas Roadhouse and Outback Steakhouse.

Advisors' Opinion:
  • [By Victor Selva]

    The firm is currently Zacks Rank # 3 - Hold, and it also has a longer-term recommendation of ��nderperfom.��For investors looking for a Zacks Rank # 1 ��Strong Buy, Ignite Restaurant Group Inc. (IRG) and The Wendy's Company (WEN) could be the options.

  • [By Seth Jayson]

    Margins matter. The more Ignite Restaurant Group (Nasdaq: IRG  ) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why we check up on margins at least once a quarter in this series. I'm looking for the absolute numbers, so I can compare them to current and potential competitors, and any trend that may tell me how strong Ignite Restaurant Group's competitive position could be.

5 Best Sliver Stocks To Own Right Now: Eco Depot Inc (ECDP)

Eco Depot, Inc. (Eco Depot), incorporated on November 2, 2004, is a development-stage company. The Company is in the business of developing an Internet e-commerce Website that will sell a range of environmentally friendly goods, energy efficient building and construction materials and sustainable home products. Eco Depot will not manufacture any equipment or goods, but will resell green products from various manufacturers. In July 2010, Eco Depot Inc acquired CS Tech (America).

Eco Depot, Inc. plans to develop and market an e-commerce enabled Website, which would attract prospective industrial clientele, businesses, municipalities and individual customers seeking cleaner technologies and products. The Company plans to market and sell through its Website goods and products that are defined as green. These green products include recycled paper counter tops, environmentally friendly paints, and recycled glass tiles. Eco Depot began the initial development of its Website (www.ecodepotinc.com.) where these products are listed.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap green stocks Eco Depot Inc (OTCMKTS: ECDP), Eco Building Products Inc (OTCMKTS: ECOB) and Profire Energy, Inc (OTCBB: PFIE) has been getting some extra attention lately in various investment newsletters thanks to paid promotions or investor relation campaigns. Of course, there is nothing wrong with properly disclosed promotions and investor relations campaigns, but small cap green stocks tend to be extra volatile when compared with other stocks. So how in greenbacks will these three small cap green stocks produce for investors? Here is a quick reality check:

Wednesday, May 27, 2015

10 Best Freight Stocks To Invest In 2016

10 Best Freight Stocks To Invest In 2016: Marten Transport Ltd (MRTN)

Marten Transport, Ltd. is a temperature-sensitive truckload carrier. The Company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. It operates throughout the United States and in parts of Canada and Mexico. The Company operates in two segments: Truckload and Logistics. During the year ended December 31, 2011, approximately 81% of its truckload revenue resulted from hauling temperature-sensitive products and 19% from hauling dry freight. Its long-haul traffic lanes are between the Midwest and the West Coast, Southwest, Southeast, and the East Coast, as well as from California to the Pacific Northwest. It provides regional truckload carrier services in the Southeast, West Coast, Midwest, South Central and Northeast regions.

The Company derives truckload revenue from fuel surcharges, loading and unloading activities, equipment detention and other ancillary services. Its operating revenue also includes revenue reported within its Logistics segment, which consists of revenue from its internal brokerage and intermodal operations, and through its 45% interest in MW Logistics, LLC (MWL), a third-party provider of logistics services to the transportation industry. Brokerage services involve arranging for another company to transport freight for the Companys customers, while it retains the billing, collection and customer management responsibilities. Intermodal services involve the transport of its trailers on railroad flatcars for a portion of a trip, with the balance of the trip using its tractors or, to a lesser extent, contracted carriers. It focuses on large food and consumer-packaged goods companies whose products require temperature-sensitive services and who ship multiple truckloads per week. As of December 31, 2011, its customers were General Mills and Kraft.

As of December 31, 2011, the Company oper! ated a fleet of 2,2 81 tractors, including 2,233 company owned tractors and 48 tractors supplied by independent contractors. The average age of its company owned tractor fleet at December 31, 2011 was approximately 2.6 years. As of December 31, 2011, it operated a fleet of 4,124 trailers. Most of its trailers are equipped with Thermo-King refrigeration units, air ride suspensions and anti-lock brakes. The average age of its trailer fleet as of December 31, 2011 was approximately 2.4 years.

Advisors' Opinion:
  • [By Seth Jayson]

    Marten Transport (Nasdaq: MRTN  ) reported earnings on July 16. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended June 30 (Q2), Marten Transport missed estimates on revenues and missed estimates on earnings per share.

  • [By Monica Gerson]

    Marten Transport (NASDAQ: MRTN) is estimated to post its Q3 earnings at $0.23 per share on revenue of $168.28 million.

    CSX (NYSE: CSX) is expected to post its Q3 earnings at $0.43 per share on revenue of $2.95 billion.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/10-best-freight-stocks-to-invest-in-2016.html

Tuesday, May 26, 2015

10 Best Electric Utility Stocks To Watch Right Now

10 Best Electric Utility Stocks To Watch Right Now: Alamos Gold Inc (AGI) Alamos Gold Inc. is engaged in the acquisition, exploration, development and extraction of precious metals in Mexico and Turkey. It owns and operates the Mulatos mine (Mulatos or the Mine) and holds the mineral rights to the Salamandra group of concessions in the State of Sonora, Mexico. The Mulatos mine is approximately 220 kilometers by air east of the City of Hermosillo. In addition, the Company owns the Agi Dagi and Kirazli advanced-stage gold development projects located in the Biga Peninsula of northwestern Turkey. Agi Dagi is located about 50 kilometers southeast of Canakkale, and Kirazli is located approximately 25 kilometers northwest of Agi Dagi. In January 2013, it acquired 14.3% interest of Aurizon Mines Ltd. (Aurizon). In August 2013, the Company acquired Esperanza Resources Corp. In September 2013, the Company announced that it has completed the acquisition of Orsa Ventures Corp. Advisors' Opinion:
  • [By Jon C. Ogg]

    AlamosGold Inc. (NYSE: AGI) was reinstated as Buy with a target price of $21 in Canada, which would translate to closer to $20 in U.S. share prices (versus $16.33 current), at BofA/Merrill Lynch.

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/10-best-electric-utility-stocks-to-watch-right-now.html

Monday, May 25, 2015

Top 10 Canadian Stocks To Invest In 2015

Outside of being a hot-button environmental issue, TransCanada's (NYSE: TRP  ) Keystone XL is having a major impact on the depressed price of Canadian crude oil. In this video, Fool.com contributor Aimee Duffy takes a look at a handful of pipeline projects that have yet to be realized that are having a devastating impact on Canadian energy stocks.

It's easy to forget the necessity of midstream operators that seamlessly transport oil and gas throughout the United States. Kinder Morgan is one of these operators, and one that investors should commit to memory due to its sheer size ��it's the third-largest energy company in the U.S. ��not to mention its enormous potential for profits. In The Motley Fool's premium research report on Kinder Morgan, we break down the company's growing opportunity ��as well as the risks to watch out for ��in order to uncover whether it's a buy or a sell. To determine whether this dividend giant is right for your portfolio, simply click here now to claim your copy of this invaluable investor's resource.

Top 5 Canadian Stocks To Own For 2016: Silvercorp Metals Inc(SVM)

Silvercorp Metals Inc. engages in the acquisition, exploration, development, and operation of silver mineral properties in China and Canada. The company holds interests in four silver, lead, and zinc mines, including the Ying Project, the HPG Project, the TLP Project, and the LM Project at the Ying Mining Camp in the Henan Province of China. It also holds interests in the GC Project, a silver, lead, and zinc mine in the Guangdong Province; and the BYP gold, lead, and zinc mine project in Hunan province, as well as the Silvertip silver, lead, and zinc mine project in northern British Columbia, Canada. The company was formerly known as SKN Resources Ltd. and changed its name to Silvercorp Metals Inc. in May 2005. Silvercorp Metals Inc. is headquartered in Vancouver, Canada.

Advisors' Opinion:
  • [By Selena Maranjian]

    Silvercorp Metals (NYSE: SVM  ) shed 50%, but that leaves it yielding 3.1% -- and it's even earning more than it's paying out, which is promising. The company,�China's biggest primary silver producer, has been in the news as an alleged scammer as well as a possible scamming victim. (It's worth noting that it has been up front about problems, rather than evading them.) In its latest quarter, net income fell 25%, due in large part to falling silver prices, but its silver production was up 17% and gold up 42%. (It produces far less gold than silver, and it also mines lead and zinc.)

Top 10 Canadian Stocks To Invest In 2015: (AMC)

AMC Entertainment Holdings, Inc., through its subsidiaries, operates as a theatrical exhibition company in the United States and internationally. As of June 30, 2011, it owned, operated, or had interests in 357 theatres and 5,098 screens in 31 states and the District of Columbia, and 4 countries outside the United States. The company was founded in 1920 and is headquartered in Kansas City, Missouri. As of August 30, 2012, AMC Entertainment Holdings, Inc. operates as a subsidiary of Dalian Wanda Group Corporation Ltd.

Advisors' Opinion:
  • [By Brian Stelter]

    AMC (AMC) will own 49.9% of the channel, BBC America, and run its day-to-day operations as well as its advertising sales and distribution arrangements. The British Broadcasting Corporation will retain a majority 50.1% stake.

  • [By DailyFinance Staff]

    The looming Fed taper has been the talk of Wall Street for months, but it still came as a surprise to investors when it actually happened. Stocks rallied Wednesday following the Fed's decision to cut its $85 billion a month purchase of bonds by $10 billion, beginning in January. Outgoing Fed Chairman Ben Bernanke said the economy continues to "make progress." The Dow Jones industrial average (^DJI) soared 292 points on the news, its third biggest one-day gain this year. The Dow also hit a closing high, as did the Standard & Poor's 500 index (^GPSC), which gained 29 points. And the Nasdaq composite (^IXIC) rose 46 points. Consider it Bernanke's final present to the market before he retires from his position atop the Fed. Among the big blue chip winners, 3M (MMM) rose 3 percent, while Exxon Mobil (XOM), Chevron (CVX) and Goldman Sachs (GS) all rose 2 percent. But Microsoft (MSFT) was flat, reflecting across the board weakness in tech stocks. Many of the biggest players on the Nasdaq lost ground despite the overall market rally. Apple (AAPL) and Twitter (TWTR) ended lower and Tesla (TSLA) lost nearly 3 percent. Part of the reason for the tech weakness was an earnings miss and a weak forecast from Jabil Circuits (JBL), a key maker of electronics. Its shares plunged 20 percent. But homebuilders were strong following a report showing that housing starts last month rose to highest level in nearly six years. Lennar (LEN), which also posted strong earnings, jumped 6 percent. William Lyon Homes rose 4 percent, KB Homes (KBH) and Toll Brothers (TOL) each rose 3.5 percent. Ford (F) shares skidded more than 6 percent after lowering its profit forecast for next year. The company also warned that it may not meet its target for 2015 and 2016. In part, Ford blames the high expenses tied its planned launch of a record number of new vehicles next year. Finally, the movie theater chain AMC Entertainment (AMC) rose 5 percent from its $18 a share IPO price. This is exp

Top 10 Canadian Stocks To Invest In 2015: Stage Stores Inc.(SSI)

Stage Stores, Inc. operates as a specialty department store retailer that offers branded and private label apparel, accessories, cosmetics, and footwear for women, men, and children in the United States. The company also offers sportswear, dresses, intimates, home and gift products, outerwear, swimwear, and other products. It primarily focuses on consumers in small and mid-sized markets. The company operates stores under the names of Bealls, Goody?s, Palais Royal, Peebles, and Stage. Stage Stores, Inc. also sells its products through its Web site. As of March 06, 2012, it operated 819 stores in 40 states. Stage Stores, Inc. is headquartered in Houston, Texas.

Advisors' Opinion:
  • [By Anna Prior]

    Stage Stores Inc.(SSI) said it agreed to sell its Steele’s retail stores to financial services firm Hilco Global later this year, which contributed to a drop in fiscal fourth-quarter earnings. The top line missed expectations, and the sales view for the year also fell below the consensus view.

  • [By Roberto Pedone]

    Another earnings short-squeeze prospect is specialty department store retailer Stage Stores (SSI), which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Stage Stores to report revenue of $397.57 million on earnings of 53 cents per share.

    Read More: Triple Your Gains With These 5 Cash-Rich Companies

    The current short interest as a percentage of the float for Stage Stores is pretty high at 11.6%. That means that out of the 30 million shares in the tradable float, 3.58 million shares are sold short by the bears. The bears have also been increasing their bets from the last reporting period by 4.2%, or by about 145,000 shares. If the bears get caught pressing their bets into a bullish quarter, then shares of SSI could easily surge sharply higher post-earnings as the shorts jump to cover some of their positions.

    From a technical perspective, SSI is currently trending above its 50-day moving average and just below its 200-day moving average, which is neutral trendwise. This stock has been trending sideways and consolidating for the last three months and change, with shares moving between $17.51 on the downside and $20.32 on the upside. Any high-volume move above the upper-end of its recent range post-earnings could trigger a big breakout trade for shares of SSI.

    If you're bullish on SSI, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some near-term overhead resistance levels at $19.91 to $20.32 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 233,200 shares. If that breakout begins post-earnings, then SSI will set up to re-test or possibly take out its next major overhead resistance levels at $23 to $25 a share.

    I would simply avoid SSI or look for short-biased trades if after earnings it fails to trigger that breakout and then takes out some key

  • [By Dan Caplinger]

    On Friday, Stage Stores (NYSE: SSI  ) will release its latest quarterly results. The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise. That way, you'll be less likely to make an uninformed knee-jerk reaction to news that turns out to be exactly the wrong move.

  • [By Jake L'Ecuyer]

    Stage Stores (NYSE: SSI) was also up, gaining 13.47 percent to $22.41 after the company reported Q4 results and announced the sale of its Steele's off-price division to a new retail unit of Hilco Global.

Top 10 Canadian Stocks To Invest In 2015: Higher One Holdings Inc.(ONE)

Higher One Holdings, Inc. provides technology and payment services in the United States. It offers a suite of disbursement and payment solutions for higher education institutions and their students. The company provides OneDisburse Refund Management product that offers higher education institutional clients with a technology service for streamlining the student refund disbursement process. It also offers CASHNet Payment suite that includes software-as-a-service products and services, such as ePayment to securely accept online payments for tuition, charges, and fees from students through credit card, pinless debit, and ACH; eBill to automate payer billing and processing functions; MyPaymentPlan to personalize students? payment plans; eMarket that allows academic, athletic, and other departments to take alumni donations, sell event tickets and other merchandise, and accept payments of event and conference registration fees; and Cashiering to operate and manage cashiering fu nctions, back office payments, and campus-wide departmental deposits. In addition, the company provides OneDisburse ID, which offers an option to combine the company?s debit card with the institution?s ID cards; OneDisburse Payroll to distribute payroll and other employee-related payments; OneDisburse PLUS product to distribute Parent PLUS loan refunds to parents on behalf of the school; and Financial Intelligence to students with an online class. Further, it provides student-oriented banking services to campus communities. Additionally, the company offers OneAccount product for students, as well as faculty, staff, and alumni, with an FDIC-insured online checking account and a debit MasterCard ATM card. Higher One Holdings, Inc. was founded in 2000 and is headquartered in New Haven, Connecticut.

Advisors' Opinion:
  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Higher One Holdings (NYSE: ONE  ) , whose recent revenue and earnings are plotted below.

  • [By Steve Symington]

    What:�Shares of Higher One Holdings, Inc (NYSE: ONE  ) rose as much as 10% early Thursday, then settled to close up around 6% after the company reported better-than-expected first-quarter results.

  • [By John Seward]

    Veritiv Corp (NYSE: VRTVW) will replace Higher One Holdings Inc (NYSE: ONE) in the S&P SmallCap 600 on Tuesday, July 1. International Paper (NYSE: IP) is spinning off its distributions solutions unit, and the new company will merge with privately held UWW Holdings to create Veritiv.

  • [By Roberto Pedone]

    One under-$10 business services player that looks poised for a run higher is Higher One (ONE), which provides technology-based refund disbursement, payment processing and data analytics services to higher education institutions and students. It also provides banking services to campus communities. This stock has been hit hard by the bears so far in 2013, with shares down by 26%.

    If you take a look at the chart for Higher One, you'll notice that this stock has been downtrending badly for the last three months, with shares plunging from its high of $11.93 to its recent low of $6.97 a share. During that downtrend, shares of ONE were consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of ONE have recently formed a double bottom chart pattern at $7.05 to $6.97 a share. This stock has now started to rebound sharply off that double bottom and move within range of triggering a near-term breakout trade.

    Traders should now look for long-biased trades in ONE if it manages to break out above some near-term overhead resistance at $7.85 a share and then once it clears its 50-day moving average at $8.11 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 196,360 shares. If that breakout triggers soon, then ONE will set up to re-test or possibly take out its next major overhead resistance levels at $9 to its 200-day moving average of $9.77 a share. This stock could even tag $11 a share if that 200-day gets taken out with volume.

    Traders can look to buy ONE off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $7.39 a share, or below $7 a share. One can also buy ONE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top 10 Canadian Stocks To Invest In 2015: SAP AG(SAP)

SAP AG provides business software primarily in Europe, the Middle East, Africa, the Americas, and the Asia Pacific Japan region. The company?s products includes SAP Business Suite software, which supports large organizations in their core business operations, such as supplier relationship, production, warehouse management, sales, administration, and customer relationship; SAP Business All-in-One, a business management software that assists midsize companies in managing various business functions, including financials, human resources, procurement, inventory, manufacturing, logistics, product development, sales, and marketing; SAP Business One, a business management application for small businesses; and SAP Business ByDesign, an on-demand solution for integrated business management applications. Its products also comprises SAP BusinessObjects Edge business intelligence and enterprise performance management solutions; Xcelsius, a data visualization software; Crystal Reports, which helps users design interactive reports; Sybase IQ, an optimized analytics server designed to deliver results for business intelligence, analytics, data warehousing, and reporting solutions; SAP solutions for sustainability; and SAP NetWeaver technology platform, which integrates information and business processes across various technologies and organizational structures. In addition, the company offers industry and solution-focused, business transformation, information technology transformation, custom development, and support services; and program, project management, quality assurance, and education and certification services. It sells its products through its subsidiaries and resellers. SAP AG has a strategic relationship with Cap Gemini S.A. to develop and deploy enterprise mobility solutions. The company was formerly known as SAP Aktiengesellschaft Systeme, Anwendungen, Produkte in der Datenverarbeitung. SAP AG was founded in 1972 and is headquartered in Walldorf , Germany.

Advisors' Opinion:
  • [By Paul Ausick]

    Big Earnings Movers: McDonald�� Corp. (NYSE: MCD) is down 0.6% at $94.59 after a so-so report and a downbeat forecast. Halliburton Co. (NYSE: HAL) is down 3.4% at $50.67 on added caution for the current quarter. V.F. Corp. (NYSE: VFC) is up 3.4% at $211.24. SAP AG (NYSE: SAP) is up 3.6% at $76.38. NVR Corp. (NYSE: NVR) is down 4.1% at $893.40.

  • [By Vanin Aegea]

    Innovation and friendliness are two stewards that software developers value highly in order to retain and attract customers. Applications that are easy to navigate and to use have proved to be highly valued by users. Some companies were able to meet the challenge and deliver tailor made products, among them are: Sap Aktiengesellschaft (SAP) and Adobe Systems (ADBE). But, does catering to customer preferences generate profits?

  • [By mitu77]

    SAP (SAP), is an established name globally, and a leader in the ERP (Enterprise Resource Planning) software solution provider, with Oracle (ORCL) the closest competitor. With a paradigm shift from in-house implementation to cloud, SAP also joined the race by providing ERP solution in a cloud environment. The strategic move of the company to focus on cloud was illustrated with SAP HANA, which is now gaining momentum and increasing its global footprints. SAP HANA has been a channel for the company to boost its top line. The company also provides various turnkey software solutions pertaining to other growth market like data mining and data warehousing.

Top 10 Canadian Stocks To Invest In 2015: El Paso Electric Company (EE)

El Paso Electric Company, a public utility company, engages in the generation, transmission, and distribution of electricity primarily in west Texas and southern New Mexico. It principally operates nuclear, natural gas, and coal power plants, as well as wind turbines. As of December 31, 2010, the company owned 6 electrical generating facilities with a net generating capacity of approximately 1,643 megawatts. It serves approximately 370,000 residential, commercial, industrial, public authority, and wholesale customers. The company sells its products to electric utilities and power marketers, as well as to oil and copper refining, and steel production facilities, universities, and the United States military installations. El Paso Electric Company was founded in 1901 and is based in El Paso, Texas.

Advisors' Opinion:
  • [By Tyler Crowe]

    If we were to pinpoint a company that�embodies�this�success�as of late, it's First Solar (NASDAQ: FSLR  ) . It just sold a 139 megawatt facility to�utility�giant -- and large coal consumer -- Southern (NYSE: SO  ) , and recently signed a power purchase deal with El Paso Electric (NYSE: EE  ) that will supply El Paso with electricity for half what it pays for power from coal. These deals also come with the announcement that the company upped guidance earlier in April which sent share prices up by 46% in one day.�

Top 10 Canadian Stocks To Invest In 2015: Cameco Corporation(CCJ)

Cameco Corporation operates as a uranium producer, supplier of conversion services, and fuel manufacturer. The company?s Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. Its operating uranium properties include the McArthur River and Key Lake, and Rabbit Lake located in Saskatchewan, Canada; the Crow Butte located in Nebraska and the Smith Ranch-Highland located in Wyoming; and the Inkai uranium deposit located in Kazakhstan. Cameco Corporation?s Fuel Services segment engages in the refining, conversion, and fabrication of uranium concentrate; and the purchase and sale of conversion services. Its products include uranium trioxide, uranium hexafluoride, and uranium dioxide. This segment also manufactures fuel bundles, reactor components, and monitoring equipment to Candu reactors; and provides nuclear fuel and consulting services to Candu operators. The company?s Electricity segment engages in the generation and sale of nuclear electricity, through its 31.6% interest in Bruce Power L.P. This segment operates four nuclear reactors at the Bruce B generating station in southern Ontario, Canada. The company was founded in 1987 and is headquartered in Saskatoon, Canada.

Advisors' Opinion:
  • [By Reuben Brewer]

    Cameco (NYSE: CCJ  ) has a lot invested in the future growth of nuclear power. And it expects good things, particularly in Asia. However, nuclear power has older plants (built decades ago) that need to be cleaned up. That's where companies like Fluor (NYSE: FLR  ) can make a buck.

  • [By Dividend]

    Cameco (CCJ) has a market capitalization of $7.64 billion. The company employs 3,470 people, generates revenue of $2.234 billion and has a net income of $254.68 million. Cameco�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $704.68 million. The EBITDA margin is 31.54 percent (the operating margin is 11.60 percent and the net profit margin 11.40 percent).

  • [By The Energy Report]

    JH: There are several companies that are in production that we follow in the U.S., such as Cameco Corp. (CCJ). Cameco produces at the Smith Ranch-Highland in the Powder River Basin. There's Uranium One, also in the Powder River Basin. There's Uranium Energy Corp. (UEC). A few near-term producers are rapidly coming online. Ur-Energy Inc. (URG) is one company we like in Wyoming.

  • [By Brian Pacampara]

    Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, uranium producer Cameco (NYSE: CCJ  ) has earned a respected four-star ranking.

Sunday, May 24, 2015

Myriad Genetics: How Low Can It Go?

Shares of Myriad Genetics (MYGN) have plunged this morning after a U.S. agency said it would pay less for its breast-cancer tests.

The Wall Street Journal has the details:

The price of a popular genetic test that predicts women’s risk of breast cancer is likely to drop in the New Year after the agency that administers Medicare benefits said it would slash its reimbursement rate for the test by half.

The rate cut goes into effect on Jan. 1, 2014, with consequences for genetic-testing companies, particularly Myriad Genetics Inc., the dominant supplier of screenings for mutations in the genes known as BRCA1 and BRCA2. Medicare will pay a maximum of $1,440 for the BRCA test, a 48.5% decline from the rate of $2,795 it paid in 2013, according to a notice published Friday afternoon on the website of the Centers for Medicare and Medicaid Services.

The announcement comes just months after the Supreme Court said that Myriad couldn’t patent the BRCA genes and allowed companies like Quest Diagnostics (DGX) to offer its own tests, the Wall Street Journal says.

JPMorgan’s Tycho Peterson and team call the decisions a “significant negative” for Myriad Genetics:

We view this confirmation of the rate cut as a significant negative for MYGN as the company will have a difficult time explaining why CMS believes the BRCA test should cost less than half of MYGN's list price ($4,040).

Primary question is how quickly this will impact private payors. With increased competition coming to the market at significantly lower prices than MYGN, we expect payors will begin to influence physicians to use competitive tests, while leaving open the option for patients to use MYGN's test if they want to pay the additional cost (+$1,500) out of pocket. In our prior physician survey (found here), all 25 physicians surveyed were willing to convert away from MYGN for a competitive product and 76% viewed price as a "very important" factor in the testing decision.

RBC Capital Markets’ Michael Yee and team consider the possibilities for Myriad:

We reiterate our Sector Perform rating given continued low visibility on reimbursement changes and revenue impacts over the next year, and increased competition vs. trying to convert revenues to new myRisk panel test; therefore, while cash flows have been solid, questions on durability and sustainability of long-term cash flow prevail. We stress-tested the DCF and the scenarios say: 1) most dire scenario of minimal 20% conversion to myRisk and -50% pricing erosion by 2017 puts value at $12/share; 2) downside scenario of 40% conversion and -45% pricing erosion yields $16/share; and 3) a reasonable base case is -40% pricing erosion and 50% conversion to myRisk, which yields $24/share. Upside bull case would be for swift conversion of revs to MyRisk (70%+ by 2016), which should get its own test code, and for this test to organically grow as more patients are eligible for testing/reimbursement due to enhanced sensitivity and accuracy.

Hot Gold Companies To Own In Right Now

Shares of Myriad Genetics have dropped 17% to $20.10 this morning, while Quest Diagnostics has dipped 0.2% to $53.97.

Friday, May 22, 2015

5 Best Long Term Stocks To Buy Right Now

5 Best Long Term Stocks To Buy Right Now: American Public Education Inc.(APEI)

American Public Education, Inc., together with its subsidiary, American Public University System, Inc., provides online postsecondary education focusing on the needs of the military and public service communities. The company operates through two universities, American Military University (AMU) and American Public University (APU) serving approximately 110,000 students in the United States and internationally. The universities share a common faculty and curriculum, which includes 87 degree programs and 69 certificate programs in disciplines related to national security, military studies, intelligence, homeland security, criminal justice, technology, business administration, education, nursing, and liberal arts. The company was founded in 1991 and is headquartered in Charles Town, West Virginia.

Advisors' Opinion:
  • [By James Brumley]

    American Public Education (APEI) has been one of the biggest victims of the DOE’s partial shutdown. The 41,000 individual online classes scheduled to begin a few days ago were reduced by 13,000 when many military and government employees lost their tuition assistance as of October 1st.

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    Non-cyclical consumer goods & services shares climbed around 0.22 percent in trading on Friday. Leading the sector was strength from American Public Education (NASDAQ: APEI) and XO Group (NASDAQ: XOXO). In trading on Friday, telecommunications services shares were relative laggards, down on the day by about 0.41 percent.

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on American Public Education ! (Nasdaq: APEI  ) , whose recent revenue and earnings are plotted below.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-long-term-stocks-to-buy-right-now-3.html

Wednesday, May 20, 2015

Investing in the Next Generation of Video Game Consoles

The launches of Microsoft's Xbox One and Sony's PlayStation 4 have started another generation of the battle for sales of video game consoles and, by extension, the battle for your living room. It's a big industry, but it's impossible to predict from a console's launch how successful it will be. That uncertainty can scare off investors, but there are ways to invest in the latest console boom without trying to pick a winner.

Making the systems
To sell millions upon millions of consoles, a lot of things need to happen. First, they need to be made and two companies are heavily involved.

The first, Advanced Micro Devices (NYSE: AMD  ) makes the processors for both Sony and Microsoft's offerings, so whether it's a PlayStation or an Xbox under the Christmas tree, there is an AMD processor at its core. Whether both consoles continue to compete for market share with relative parity or one dominates the other, AMD wins.

AMD's primary business is in making processors for computers and between that and their sudden domination of the console market, they are extremely well positioned for a turnaround. Analysts are predicting a return to profitability, and a big gain from the console ramp-up could easily make this the turnaround story of 2014. Stiff competition from Intel on the PC side of things has given them some lean years, but with over $1 billion in cash on hand, there's every reason to bet on this success.

But all those AMD chips and high-end components don't just put themselves together, and that's where Foxconn comes in. The consumate Chinese manufacturer of other peoples' gadgets is involved in the manufacture of both consoles, and that's a nice position to be in. I'm not a huge fan of Foxconn's incredibly low profit margin business style, but there's no denying they're good at what they do.

Games
Out of the box neither an Xbox One or a PlayStation 4 can do much. These are video game systems, and they need games to be worthwhile. While both Sony and Microsoft do make some of their own games, the lion's share of the game market is third-party developers.

While some of the software companies, like Japan-centric Konami and Square clearly would benefit more from PlayStation 4 becoming the worldwide standard, most of the major software players will take advantage of the internal similarities of the two systems, and release their games for both.

Electronic Arts (NASDAQ: EA  ) and Take-Two Interactive (NASDAQ: TTWO  ) are both going to benefit, as their respective sports and action games get reboots on new systems.

The benefit is not just novelty, it's price. The last couple of years of this generation, and indeed any generation, the "new" games fall out of favor quickly and end up in bargain bins well below launch price just a few months out of the gate. On the new systems, there is no competition from used games yet, and the prices will stay higher for longer, helping margins. Higher production costs will offset this somewhat, however.

While earnings will be improved for both in the near term, that makes me nervous and I'm not sure either is a buy at current levels. By contrast, Activision Blizzard (NASDAQ: ATVI  ) sports much better margins, a much higher current ratio (over 5 versus over 1 for the others), and even a small dividend.

Activision isn't as pure a play on the consoles, with its Blizzard division almost exclusively focused on PC gaming, but Blizzard's knack for long-term successful titles will provide the Activision division with a cash-flow cushion that will allow them to take risks the others may not be able to afford. In the last generation that meant some huge hits, and there's no reason to doubt that again this time.

Buying it all
One last play, lost in all of this, is the retail play. Lots of places sell games, from Wal-Mart to Amazon, but the pure play is what it's been for years, GameStop (NYSE: GME  ) , and its worth considering.

People have been predicting the death of GameStop and the rise of digital distribution for years. Buying games on the console and downloading them is an option for some of us, but while broadband is more and more common nationwide, the high speeds needed to download huge, Blu-Ray-sized games are still comparatively expensive and uncommon. Even where they do exist, download caps at Internet providers mean dedicating tens of gigabytes of bandwidth to downloading a single game is not an option for many.

GameStop still has a valuable niche in gaming retail, and there's a lot to like about the cash-rich, debt-free company, with its consistent earnings and its sub-1 PEG ratio.

With everybody predicting a big win for either Sony or Microsoft, there's a lot of temptation to think you have to gamble on one or the other to play the game market. But whether you're into the hardware side with AMD, the software side with Activision, or the retail aspect with GameStop, some of the most compelling plays in the sector don't depend on either side winning outright.

More growth ideas from the Motley Fool
Tired of watching your stocks creep up year after year at a glacial pace? Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.

Tuesday, May 19, 2015

Top Biotech Stocks To Own For 2015

Popular Posts: 10 Best “Strong Buy” Stocks ��GMK TRGP TPL and more10 Oil and Gas Stocks to Buy Now15 Oil and Gas Stocks to Sell Now Recent Posts: Biggest Movers in Healthcare Stocks Now – HGR SLXP MD MWIV Biggest Movers in Technology Stocks Now – MITL CNQR WNS IACI Hottest Basic Materials Stocks Now – GPK FBR CW PCP View All Posts 11 Biotechnology Stocks to Buy Now

This week, 11 biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

Hot Defense Companies To Own In Right Now: Sucampo Pharmaceuticals Inc (SCMP)

Sucampo Pharmaceuticals, Inc., incorporated on December 9, 2008, is a global biopharmaceutical company focused on research, discovery, development and commercialization of drugs based on ion channel activators known as prostones. The Company�� prostone-based compounds target the ClC-2 and big potassium (BK), ion channels. It is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other therapeutic applications of its drug technology. The Company�� products include AMITIZA (lubiprostone) and RESCULA (unoprostone isopropyl).

AMITIZA

The Company�� AMITIZA is being marketed in the United States for three gastrointestinal indications under a license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. The three gastrointestinal indications include chronic idiopathic constipation (CIC), in adults, irritable bowel syndrome with constipation (IBS-C), in adult women, and opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration (FDA), in April 2013. In Japan, AMITIZA is marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd. (Abbott), for the gastrointestinal indication of chronic constipation (CC), excluding constipation caused by organic diseases. In Switzerland, the Company is marketing AMITIZA.

RESCULA

The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People�� Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP), in patients with open-angle glaucoma or ocular hypertension in the United States. RESCULA may be used as an agent or concomit! antly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.

Advisors' Opinion:
  • [By James Brumley]

    Still, for the nimble who know when to get out, OREX is one of the few cheap stocks worth a closer look.

    Sucampo Pharmaceuticals (SCMP)

    Finally, though the price of $7.60 clearly qualifies it as one pf the cheapest of the cheap stocks out there in the pharmaceutical world, that’s not the reason Sucampo Pharmaceuticals (SCMP) may be worth a look here. It’s the 30% slide we’ve seen SCMP stock suffer since peaking in mid-January. It’s not a pullback that’s bound to go unchallenged by the bulls.

  • [By Roberto Pedone]

    Another under-$10 stock that's starting to trend within range of triggering a major breakout trade is Sucampo Pharmaceuticals (SCMP), which is engaged in the discovery, development and commercialization of proprietary drugs based on prostones, and other novel drug technologies. This stock is off to a decent start in 2013, with shares up by 26%.

    If you take a look at the chart for Sucampo Pharmaceuticals, you'll notice that this stock has been downtrending badly for the last four months, with shares dumping hard from its high of $10.48 to its recent low of $5.40 a share. During that downtrend, shares of SCMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, the downside volatility for SCMP looks to be over in the short-term since the stock has started to reverse its downtrend and enter an uptrend. That reverse is quickly pushing shares of SCMP within range of triggering a major breakout trade above a key downtrend line.

    Traders should now look for long-biased trades in SCMP if it manages to break out above some near-term overhead resistance levels at $6.33 to $6.66 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 115,383 shares. If that breakout triggers soon, then SCMP will set up to re-test or possibly take out its next major overhead resistance levels at $7.09 to $7.67 a share. Any high-volume move above those levels will then give SCMP a chance to tag $8 to $9 a share.

    Traders can look to buy SCMP off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $5.58 to $5.40 a share. One can also buy SCMP off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Top Biotech Stocks To Own For 2015: Bio-Path Holdings Inc (BPTH)

Bio-Path Holdings Inc is a development stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc. is engaged in the business of developing cancer therapeutics. As of December 31, 2011, the Company had licenses from The University of Texas M. D. Anderson Cancer Center (MD Anderson) for three lead products and nucleic acid delivery technology, including tumor targeting technology. The licenses provide drug delivery platform technology with composition of matter intellectual property for antisense that enables systemic delivery of antisense, formulation intellectual property for systemic delivery of small interfering Ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. The Company issued a press release announcing that the United States Food and Drug Administration (FDA) had allowed an IND (investigational new drug) for its lead cancer drug candidate liposomal BP-100-1.01 (or Liposomal Grb-2 or L-Grb-2) to proceed into clinical trials.

In February, 2012, the Company completed requirements for treating patients in the second cohort. The dose being used for treatment in the third cohort is double the dose that was used to treat patients in the second cohort. At the end of February, 2012, enrollment continued in the third cohort of the clinical trial and patients are being treated.

BP-100-1.01

BP-100-1.01 is the Company's lead lipid delivery antisense drug candidate, which is being clinically tested in patients having acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). Receipt of an IND allowed the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients. Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center. As of December 31, 2011, the trial is in the middle of ! testing the third dose in patients.

BP-100-2.01

BP-100-1.02 is Liposomal Bcl-2 (also L-Bcl-2), another liposomal antisense drug candidate that was licensed from MD Anderson. This drug has pre-clinical testing data package. The target protein for this drug candidate, Bcl-2, is involved in regulating programmed cell death. In cancer, the Bcl-2 protein can over-express, which can lead to a situation, in which the Bcl-2 protein blocks the cell�� normal death signals, making the cancer cell resistant to chemotherapy. Types of cancer potentially treatable with L-Bcl-2 include lymphoma, prostate cancer, small cell lung cancer, breast cancer, melanoma, chronic lymphoid leukemia (CLL) and several others.

Advisors' Opinion:
  • [By Lisa Levin]

    Bio-Path Holdings (NASDAQ: BPTH) shares declined 5.66% to touch a new 52-week low of $2.50. Bio-Path shares have jumped 349.15% over the past 52 weeks, while the S&P 500 index has gained 19.24% in the same period.

Top Biotech Stocks To Own For 2015: Juno Therapeutics Inc (JUNO)

Juno Therapeutics, Inc. (Juno) is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR), and high-affinity T cell receptor (TCR), technologies to genetically engineer T cells to recognize and kill cancer cells. Through genetic engineering, the Company inserts a gene for a particular CAR or TCR construct into the T cell that enables it to better recognize cancer cells. Its CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas its TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

To provide treatment, the Company harvests blood cells from a cancer patient, separate the appropriate T cells, activate the cells, insert the gene sequence for the CAR or TCR construct into the cells��Deoxyribonucleic Acid (DNA), and grow these modified T cells to the desired dose level. The modified T cells can then be infused into the patient or frozen and stored for later infusion. Once infused, the T cells are designed to multiply, through a process known as cell expansion, when they encounter the targeted proteins and to kill the targeted cancer cells.

CD19-Directed Product Candidates

The Company�� product candidates, such as JCAR015, JCAR017, and JCAR014, which use CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. The Company has rights to commercialize each of these product candidates across the world. The Company�� JCAR015 is an advanced development product candidate, and it has demonstrated clinically meaningful complete remission rates in adult patients with r/r ALL. JCAR015 uses the CD28 costimulatory domain and CD3 enriched peripheral blood mononuclear cells (PBMC), which requires fewer process steps for! manufacture than its defined cell composition product candidates. JCAR015 is being tested in a Phase I open label clinical trial of patients with r/r ALL for the treatment of refractory chronic lymphocytic leukemia.

JCAR017 also targets CD19, but differs from JCAR015 in several important respects. JCAR017 uses the 4-1BB costimulatory domain and a defined cell composition of CD4+ T cells and CD8+ T cells. JCAR017 is in development for pediatric patients with r/r ALL. JCAR017 is being evaluated in a Phase I/II clinical trial in pediatric r/r ALL.

JCAR014 also targets CD19. JCAR014 uses the 4-1BB costimulatory domain and is composed of CD8+ central memory T cells and CD4+ T cells in a defined ratio. JCAR014 is being evaluated in a Phase I/II trial as a treatment for a number of B cell malignancies in patients relapsed or refractory to standard therapies.

Additional Product Candidates

The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers not targeted by CD19-directed products, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung, and pancreatic cancers, as well as B cell malignancies that do not express CD19. The Company�� CD22 is a cell surface protein widely expressed on B lymphocytes. It is expressed by B cell malignancies, including non-Hodgkin�� lymphoma (NHL), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). The Company�� L1CAM, also known as CD171, is a cell-surface adhesion molecule that plays an important role in the development of a normal nervous system. It is overexpressed in neuroblastoma, and there is increasing evidence of aberrant expression in a variety of solid organ tumors, including glioblastoma and lung, pancreatic, and ovarian cancers.

The Company�� MUC-16 is a protein overexpressed in the ovarian cancers, but not on the surface of normal ovary cells. CA-125 is a protein found in the ! blood of ! ovarian cancer patients that results from the cleavage of MUC-16. CA-125 levels in the blood are a common test for ovarian cancer progression because they correlate with cancer progression. Its MUC-16/IL-12 product candidate uses its armored CAR technology. IL-12 is a cytokine that can help overcome the inhibitory effects that the tumor micro-environment can have on T cell activity.

The Company�� ROR-1 is a protein expressed in the formation of embryos, but in normal adult cells its surface expression is predominantly found at low levels on adipocytes, or fat cells, and briefly on precursors to B cells, or pre-B cells, during normal B cell maturation. ROR-1 is overexpressed on a variety of cancers including a subset of non-small cell lung cancer, triple negative breast cancer, pancreatic cancer, and prostate cancer. It is expressed on B cell chronic lymphocytic leukemia and mantle cell lymphoma. The Company�� high-affinity TCR T cell product candidate targets WT-1, an intracellular protein that is overexpressed in a number of cancers, including adult myeloid leukemia, or AML, and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Advisors' Opinion:
  • [By John Udovich]

    Small cap cancer drug stock Kite Pharma Inc (NASDAQ: KITE) has surged after announcing a�strategic research collaboration and license agreement with Amgen, Inc (NASDAQ: AMGN)�involving Chimeric Antigen Receptors (CAR) ��meaning its worth taking a closer look at the stock, which had an IPO last June,�along with potential peers�Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) and Juno Therapeutics (NASDAQ: JUNO) which are players in the CAR therapies space and had more recent IPOs.

Top Biotech Stocks To Own For 2015: Enanta Pharmaceuticals Inc (ENTA)

Enanta Pharmaceuticals, Inc., incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. The Company is discovering and developing novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes-protease (partnered with AbbVie, the former research-based pharmaceutical business of Abbott Laboratories), NS5A (partnered with Novartis) and nucleotide polymerase, as well as a host targeted antiviral (HTA) inhibitor class targeted against cyclophilin. ABT-450, discovered through its collaboration with AbbVie, is a protease inhibitor that has demonstrated in vitro potency against known resistant HCV mutants.

In Phase I studies, ABT-450 co-administered with ritonavir, a commonly used boosting agent to increase the blood concentrations of many protease inhibitors, was shown to be safe and well tolerated. Co-administration of ABT-450 with ritonavir, which it refers to together as ABT-450/r, has enabled once-daily dosing of ABT-450. Phase II studies have demonstrated the efficacy of ABT-450/r in patients with chronic HCV, and other interferon-free Phase II studies of ABT-450-containing regimens continue. AbbVie is developing a next-generation protease inhibitor discovered within the Enanta-AbbVie collaboration. EDP-239 is the NS5A inhibitor discovered by the Company. The Company also has a program to develop nucleotide inhibitors to HCV NS5B polymerase, which is another DAA mechanism considered to have a barrier to resistance. The Company�� Bicyclolide antibiotic product candidate is EDP-788, which it is developing for use as an intravenous drug in the hospital setting and for oral dosing in the home setting. EDP-788 is a prodrug, which means that it is inactive until it is converted in the body into an active compound. EDP-788 is! a water-soluble molecule which, when administered in preclinical models, is cleanly and rapidly converted into the active compound.

Advisors' Opinion:
  • [By Ben Levisohn]

    The fundamentals of the biotech industry appear strong as measured by a robust list of ongoing and expected product launches. Large-cap biotech companies under our coverage (Alexion Pharmaceuticals, Amgen, Celgene, Gilead, Vertex Pharmaceuticals (VRTX)) all have ongoing or anticipated product launches in 2015. These launches…AbbVie (ABBV) /�Enanta Pharmaceuticals (ENTA) Viekirax + Exviera for hepatitis C…Other high-visibility launches include the expected launches of PCSK9 antibodies, evolocumab from�Amgen and alirocumab from Sanofi (SNY) / Regeneron (REGN) for high cholesterol, anticipated in 3Q:15. Although the expectation is for a slow ramp-up until cardiovascular outcome data (no later than 2017), the market is large enough to allow fast launches. For Celgene, Gilead, Medivation (MDVN) and Vertex, the launches are for their most important products; therefore the progress of the launches will be particularly important to watch.

  • [By George Budwell]

    Normally, such strong efficacy results would be hailed as a major achievement. However, these results are actually less impressive than those by competing drug's developed by AbbVie (NYSE: ABBV  ) , Enanta Pharmaceuticals (NASDAQ: ENTA  ) and Gilead. Bristol-Myers' therapy also has a treatment duration double that of Gilead's drug Sovaldi for genotype 1 patients. So, while these results are impressive in their own right, the therapy's commercial prospects may be limited due to the presence of superior competitors in the market.�

Top Biotech Stocks To Own For 2015: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors' Opinion:
  • [By Charles Rice, Associate Editor - November 6, 2013 Money Morning]

    By acquiring Brazil's Medley Pharmaceuticals in 2009, Sanofi SA (NYSE ADR: SNY) became the largest generic pharmaceutical manufacturer in Latin America. The company holds a 12% market share in Brazil and reported annual revenue for its generics business of around $2.4 billion, a 5% increase over 2011 in constant exchange rates. Sanofi reported 2012 earnings of approximately $46 billion.

Top Biotech Stocks To Own For 2015: TESARO Inc (TSRO)

TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.

Rolapitant

Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.

TSR-011

TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.

The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.

Advisors' Opinion:
  • [By Ben Levisohn]

    Werber and Eckhard’s favorites include Gilead (GILD) and Celgene (CELG), and they find the “risk/reward…compelling” in Medivation (MDVN) and Tesaro (TSRO).

  • [By Jake L'Ecuyer]

    Equities Trading UP
    Tesaro (NASDAQ: TSRO) shares shot up 20.78 percent to $29.00 after the company reported successful primary and secondary endpoints in final Phase 3 trial for rolapitant.

Monday, May 18, 2015

Hold the Champagne, Congress Is Just Getting Started

Stocks finished in the green for a third consecutive day on Monday as hope for a deal that would avert a debt default and reopen the government grew throughout the session.

Things started off a bit on the rocky side however as the DJIA was down more than 100 points two minutes after the opening bell. It turns out that the optimism which had pushed stocks up on Friday had quickly reversed after the politicians failed to make any substantive progress over the weekend.

And before investors could pour that first cup of coffee, there was a sea of red numbers scrolling wildly at the corner of Broad and Wall.

For those keeping score at home, the DJIA has advanced an eye-popping 825 points over the past week. The S&P 500 has moved up by 3.2 percent since last Wednesday's low and the NASDAQ closed out Monday's session just a whisker away from its highest close since the spring of 2000.

And speaking of new highs, both the Russell 2000 (small-caps) and the S&P 400 (mid-caps) indices finished Monday's session at fresh all-time highs. So, it will suffice to say that the fear of what might happen to the country should Congress do the unthinkable isn't sending investors underneath their desks at the present time.

"Hopium" Revisited

Despite all the fear mongering and the doom-and-gloom being espoused by the popular press, word that Senate Majority Leader Harry Reid was "optimistic that a deal would be reached this week" managed to turn traders' frowns upside down around mid-morning on Monday.

Then the reports that the White House was scheduled to meet with Congressional leaders Monday afternoon gave the dip buyers a reason to get busy again and for shorts to continue to cover. In short, the market once again appeared to be running on "hopium."

The Latest Plan

Since the deadline clock continues to tick and time is running out, here's the latest on the debt/budget drama... On Sunday, Senate leaders (Harry Reid and Mitch McConnell) began working on plan in response ! to talks breaking down between White House and House Republicans. It was more of the same as Obama rejected the House proposal that would have raised the debt ceiling for 6 weeks in exchange for immediate negotiations on 2014 spending levels and a long-term deficit reduction deal.

The President's rejection was not terribly surprising since the House bill would not have reopened the government and also restricted the Treasury from using "extraordinary measures" to extend the debt ceiling deadline. However, on Monday, Senate Majority Leader Reid said that he was optimistic about a deal that he and Senate Minority Leader McConnell had been working on.

Perhaps the most encouraging development was the cancellation of a meeting between Obama, Biden, Boehner, Reid, McConnell, and Pelosi. At first, the algos knocked stocks back Monday as the headline that the meeting was being cancelled hit the wires. However, within minutes the indices recovered when it was announced that the reason for the cancellation was the Senators were making progress and needed more time.

Top Integrated Utility Companies To Invest In 2016

Reading The Fine Print

At this stage, the market assumes that Senators Reid and McConnell will be able to broker a deal to raise the debt ceiling and reopen the government. In addition, since the plan is expected to be bipartisan in nature and originates in the Senate, it is further assumed that Speaker Boehner will bring such a measure to a vote in the House - and that it will pass.

However, before the champagne corks start to fly and the celebration begins, investors should read the fine print.

According to reports, the current plan being worked on by Reid and McConnell will be another "kick the can" type of solution and would only provide enough funding for the government to operate until January 15, 2014. The problem is January 15 is also the date when the ! second ro! und of automatic "sequestration cuts" from the 2011 Budget Control Act kicks in. As such, the "solution" to the current problem actually sets up another round of "sequester" battles.

And given that this Congress can't seem to agree on anything - ever - it would appear that the current mess is likely to stick around for at least a couple more months. So, in short... here we go again.

Mr. David Moenning is a full-time professional money manager and is the President and Chief Investment Strategist at Heritage Capital Management. He focuses on stock market risk management, stock analysis, stock trading, market news and research. Click here to claim a free copy of Dave's Special Report on changes in the current market.

Friday, May 15, 2015

Hot Food Companies To Invest In Right Now

Hot Food Companies To Invest In Right Now: Lifeway Foods Inc (LWAY)

Lifeway Foods, Inc., (Lifeway), incorporated on May 19, 1986, is engaged in the manufacturing of probiotic, cultured, functional dairy and non-dairy health food products. The Company's primary products are kefir sold under the name Lifeway Kefir and Helios Nutrition Organic Kefir; a line of yogurts sold under the Lassi brand, and BasicsPlus, a dairy based immune-supporting dietary supplement beverage. In addition to the drinkable products, Lifeway manufactures Lifeway Farmer Cheese, a line of various farmer cheeses, a line of gourmet cream cheeses, and Sweet Kiss, a fruit sugar-flavored spreadable cheese similar in consistency to cream cheese. The Company also manufactures and markets a vegetable-based seasoning under the Golden Zesta brand. Lifeway manufactures all of its products at Company-owned facilities and distributes its products throughout the United States.

Lifeway's primary product, kefir is a fermented dairy product. Lifeway's Kefir is a dri nkable product intended for use as a breakfast meal or a snack, or as a base for lower-calorie dressings, dips, soups or sauces. Kefir is also used as the base of Lifeway's plain farmer's cheese, a cheese made without salt, sugar or animal rennet. In addition, kefir is the primary ingredient of Lifeway's Sweet Kiss product, a fruit sugar-flavored, cream cheese-like spread which is intended to be used as a dessert spread or frosting. Lifeway's Kefir is a drinkable kefir product manufactured in 10 regular and low-fat varieties, including plain, pomegranate, raspberry, blueberry, strawberry, cherry, peach, banana-strawberry, cappuccino and vanilla, and sold in 32-ounce containers and 8-ounce single serving containers featuring color-coded caps and labels describing nutritional information. The kefir product is marketed under the name Lifeway's Kefir and is sol! d by retailers from their dairy sections.

Lifeway's Organic Kefir meets the organic standards a nd specifications of the United States Department of Agricul! ture for organic products and is manufactured in five flavors: plain, wildberry, raspberry, strawberry and peach. Lifeway's Organic Kefir is sweetened with organic cane juice. Lifeway's Slim6 is a line of low-fat kefir beverages with no added sugar designed for consumers who follow low-carbohydrate diets. Lifeway's Slim6 has only eight grams of carbohydrates and 2.5 grams of fat per 8-ounce serving and is available in five flavors: strawberries n' cream, mixed berry, tropical fruit, strawberry-banana and an original, unsweetened version. ProBugs is a kefir product that contains 10 live and active kefir cultures. Aimed at children ages 2-9, ProBugscomes in three flavors, Sublime Slime Lime, Orange Creamy Crawler and Goo-Berry Pie and is packaged in no spill spout pouches designed as cartoon bug characters Peter, Polly and Penelope ProBug.

Farmer Cheese is based on a cultured soft cheese and is intended to be used in a variety of recipes as a low fat, low- cholesterol, low-calorie substitute for cream cheese or ricotta, and is available in various styles. Sweet Kiss is a sweet cheese probiotic spread available in five flavors: plain, plain with raisins, apple, peach and chocolate. Elita and Bambino cheeses are low-fat, low-cholesterol kefir based cheese spreads, which are marketed as an alternative to cream cheese. Krestyanski Tworog is a European-style kefir-based soft style cheese which can also be used in a variety of recipes, eaten with a spoon, used as a cheese spread, or substituted in recipes for cream cheese, ricotta cheese or cottage cheese and is marketed to consumers of various Eastern European ethnicities.

Basics Plus is a kefir-based beverage product designed to support gastrointestinal functions and the immune system. Kefir Starter is a powdered form of kefir that is sold in envelope p! ackets an! d allows a consumer to make his or her own drinkable kefir at home by adding milk. Lifeway continues to deve lop sales of this product through the Internet. Lassi is a c! ultured d! rink inspired by the traditions of India and is sold in 8-ounce containers in two flavors, strawberry and mango. Golden Zesta is a vegetable-based seasoning, which, because of its low sodium content, may also be used as a salt substitute and is marketed to delicatessens, gourmet shops and ethnic grocers. Helios Nutrition Organic Kefir is a kefir product made from organic milk and manufactured with a blend of active cultures. It is sold in 8 and 32 ounce bottles and made in five flavors: peach, plain, strawberry, vanilla and raspberry.

The Company competes with Danone Foods, Inc.

Advisors' Opinion:
  • [By Lisa Levin]

    Dairy Products: This industry tumbled 2.12% by 10:50 am. The worst stock within the industry was Lifeway Foods (NASDAQ: LWAY), which fell 0.9%. Lifeway Foods' PEG ratio is 3.56.

  • [By Rich Smith]

    Shares of Lifeway Foods (NASDAQ: LWAY  ) are on a tear, up nearly a full $1 (or 8.3%) since reporting earnings last week. But is the price spike justified? Let's find out.

  • [By James Brumley]

    Once the budget impasse is wrapped up though, a new Dairy Stabilization Act should be right around the corner. That’s good news for a small-cap company like dairy farm Lifeway Foods (LWAY), which saw its shares fall nearly 25% over the course of August and September when the budget impasse was shaping up.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/hot-food-companies-to-invest-in-right-now.html